Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Expression of Apolipoprotein B Epitopes in Very Low Density Lipoprotein Subtractions

Expression of Apolipoprotein B Epitopes in Very Low Density Lipoprotein Subtractions Epitope expression was studied in both denatured apolipoprotein B (apo B) on Western blots and in intact low density lipoprotein (LDL) and very low density lipoprotein subtractions VLDL1(Sf120-400), VLDL2(Sf60-120), and VLDL3(S120-60) in competitive binding immunoassays with the aid of six monoclonal anti-LDL antibodies. The apo B in all lipoprotein fractions was shown to bind to all antibodies, but significant differences in apo B epitope expression were observed. On the average, the immunoreactivity of VLDL subtractions (expresssed as binding affinity and as relative 125I-LDL displacing potency) decreased with increasing flotation rate. Similarly, VLDL, was less immunoreactive than lipolyzed “remnants” of VLDL, after treatment with bovine milk lipoprotein lipase. The results indicate that, even when lipoprotein fractions obtained from the same individual and having the same kind of apo B subspecies were compared, significant differences in immunoreactivity occurred due to the modulating effect of other lipoprotein components on apo B epitope expression. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis Wolters Kluwer Health

Expression of Apolipoprotein B Epitopes in Very Low Density Lipoprotein Subtractions

Loading next page...
 
/lp/wolters-kluwer-health/expression-of-apolipoprotein-b-epitopes-in-very-low-density-br7ercqhVj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Copyright
© 1984 by American Heart Association, Inc.
ISSN
0276-5047

Abstract

Epitope expression was studied in both denatured apolipoprotein B (apo B) on Western blots and in intact low density lipoprotein (LDL) and very low density lipoprotein subtractions VLDL1(Sf120-400), VLDL2(Sf60-120), and VLDL3(S120-60) in competitive binding immunoassays with the aid of six monoclonal anti-LDL antibodies. The apo B in all lipoprotein fractions was shown to bind to all antibodies, but significant differences in apo B epitope expression were observed. On the average, the immunoreactivity of VLDL subtractions (expresssed as binding affinity and as relative 125I-LDL displacing potency) decreased with increasing flotation rate. Similarly, VLDL, was less immunoreactive than lipolyzed “remnants” of VLDL, after treatment with bovine milk lipoprotein lipase. The results indicate that, even when lipoprotein fractions obtained from the same individual and having the same kind of apo B subspecies were compared, significant differences in immunoreactivity occurred due to the modulating effect of other lipoprotein components on apo B epitope expression.

Journal

ArteriosclerosisWolters Kluwer Health

Published: Mar 1, 1984

There are no references for this article.